Clinical Trials

Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Phase 2/3 Recruiting

316 enrolled

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04771130 2026-04-23

A Study of BGB-11417 in Participants With Myeloid Malignancies

Phase 1/2 Recruiting

260 enrolled

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT05428969 2026-04-23

BEXMAB

181 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT06656494 2026-04-13

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

266 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06419634 2026-04-08

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

105 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04227847 2026-04-07

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

178 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Phase 1/2 Recruiting

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05275439 2026-03-18

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

106 enrolled 28 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04266301 2026-01-13

STIMULUS-MDS2

Phase 3 Terminated

530 enrolled 29 charts

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04937166 2025-11-10

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

25 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

MyeloidOther hematologic neoplasmThoracic

116 enrolled 36 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT03268954 2025-10-29

PANTHER

Phase 3 Completed

454 enrolled 41 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04581512 2025-10-14

Study to Evaluate the Safety and Tolerability of EP0042

Phase 1/2 Recruiting

70 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05168202 2025-09-25

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

56 enrolled 24 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05209152 2025-07-14

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

7 enrolled 16 charts

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04603001 2025-06-27

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

260 enrolled

336 enrolled 48 charts 1 FDA

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Phase 1/2 Completed

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

38 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

241 enrolled

Phase 1/2 Active not recruiting

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04730258 2025-05-18

TWT-202

72 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT05609942 2025-04-10

AZURE

9 enrolled

Leukemia, Mast-Cell, Mastocytosis, Systemic, Myelodysplastic-Myeloproliferative Diseases

NCT03931291 2025-03-17

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

33 enrolled 7 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02807558 2024-12-13

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

155 enrolled 24 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04275518 2024-10-15

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03814005 2024-09-05

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

17 enrolled 33 charts

Liver Diseases, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Renal Insufficiency

NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Phase 1/2 Withdrawn

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04243785 2024-03-20

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

80 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04912063 2024-02-26

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

40 enrolled

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT05641259 2024-02-02

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Phase 1 Unknown

198 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04358393 2024-02-01

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Phase 1/2 Unknown

69 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

21 enrolled

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02367456 2024-01-19

BRIGHT 1012

73 enrolled 31 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04842604 2023-12-18

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Phase 3 Completed

14 enrolled 11 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02543879 2023-11-21

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

94 enrolled

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03593915 2023-11-09

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

20 enrolled 13 charts

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelomonocytic, Chronic

NCT02782468 2023-11-03

A Study of Pevonedistat in Adult East Asian Participants

23 enrolled 23 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05048498 2023-10-17

Pharmacokinetics, Tolerability and Safety of NEX-18a

2 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06008405 2023-09-06

Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Phase 1 Unknown

48 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05970822 2023-08-01

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Phase 1 Unknown

32 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03465540 2023-04-12

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

24 enrolled 21 charts

Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02775903 2023-02-28

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

213 enrolled 35 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03614728 2023-02-06

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

30 enrolled 29 charts

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04866056 2022-12-01

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

1 enrolled

Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT02610777 2022-09-19

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

120 enrolled 39 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04264806 2022-05-20

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02587598 2021-12-08

Study of INCB053914 in Subjects With Advanced Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

97 enrolled 40 charts

Leukemia, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT02319369 2021-10-11

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

74 enrolled 30 charts